Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 16, 2013, Pages

  Chen, Shih Shih ^a   Batliwalla, Franak ^a   Holodick, Nichol E ^a   Yan, Xiao Jie ^a   Yancopoulos, Sophia ^a   Croce, Carlo M ^b   Rothstein, Thomas L ^a,c   Chiorazzi, Nicholas ^a,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; IMMUNOGLOBULIN M; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLOOD; BONE MARROW; CELL CLONE; CELL DIVISION; CELL EXPANSION; CELL GROWTH; CELL PROLIFERATION; CELL TRANSPORT; CLONE; CONTROLLED STUDY; DISEASE COURSE; GENE; GENE EXPRESSION; GENE REARRANGEMENT; MOUSE; NONHUMAN; PERITONEUM; PERITONEUM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; VIRULENCE;

ANIMALS; AUTOANTIGENS; B-LYMPHOCYTES; CELL PROLIFERATION; GENE EXPRESSION PROFILING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE TRANSFUSION; MICE; MICE, SCID; MICE, TRANSGENIC; PHOSPHATIDYLCHOLINES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANTIGEN, B-CELL; SELECTION, GENETIC; SIGNAL TRANSDUCTION; V(D)J RECOMBINATION;

MURINAE;

EID: 84876266564     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1300616110     Document Type: Article

References (48)

1. Chiorazzi N, Ferrarini M (2003) B cell chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21:841-894.
2. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804-815.
3. Stevenson FK, Caligaris-Cappio F (2004) Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 103(12):4389-4395.
4. Messmer BT, et al. (2004) Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 200(4):519-525.
5. Tobin G, et al. (2004) Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 104(9):2879-2885.
6. Fais F, et al. (1998) Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102(8):1515-1525.
7. Stamatopoulos K, et al. (2007) Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 109(1):259-270.
8. Hervé M, et al. (2005) Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115(6):1636-1643.
9. Damle RN, et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840-1847.
10. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6):1848-1854.
11. Dühren-von Minden M, et al. (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489(7415):309-312.
12. Bichi R, et al. (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99(10):6955-6960.
13. Narducci MG, et al. (2000) Regulation of TCL1 expression in B-and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 60(8):2095-2100.
14. Yan XJ, et al. (2006) B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 103(31):11713-11718.
15. Lanemo Myhrinder A, et al. (2008) A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 111(7):3838-3848.
16. Catera R, et al. (2008) Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 14(11-12):665-674.
17. Mercolino TJ, Arnold LW, Hawkins LA, Haughton G (1988) Normal mouse peritoneum contains a large population of Ly-1+ (CD5) B cells that recognize phosphatidyl choline. Relationship to cells that secrete hemolytic antibody specific for autologous erythrocytes. J Exp Med 168(2):687-698.
18. Cabiedes J, et al. (2002) Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects. J Autoimmun 18(2):181-190.
19. Bhat NM, Bieber MM, Spellerberg MB, Stevenson FK, Teng NN (2000) Recognition of auto-and exoantigens by V4-34 gene encoded antibodies. Scand J Immunol 51(2): 134-140.
20. Guchhait P, López JA, Thiagarajan P (2004) Characterization of autoantibodies against sulfatide from a V-gene phage-display library derived from patients with systemic lupus erythematosus. J Immunol Methods 295(1-2):129-137.
21. Arnold LW, McCray SK, Tatu C, Clarke SH (2000) Identification of a precursor to phosphatidyl choline-specific B-1 cells suggesting that B-1 cells differentiate from splenic conventional B cells in vivo: Cyclosporin A blocks differentiation to B-1. J Immunol 164(6):2924-2930.
22. Suljagic M, et al. (2010) The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 116(23):4894-4905.
23. Casali P, Schettino EW (1996) Structure and function of natural antibodies. Curr Top Microbiol Immunol 210:167-179.
24. Chumley MJ, Dal Porto JM, Cambier JC (2002) The unique antigen receptor signaling phenotype of B-1 cells is influenced by locale but induced by antigen. J Immunol 169(4):1735-1743.
25. Chumley MJ, et al. (2000) A VH11V kappa 9 B cell antigen receptor drives generation of CD5+ B cells both in vivo and in vitro. J Immunol 164(9):4586-4593.
26. Morris DL, Rothstein TL (1993) Abnormal transcription factor induction through the surface immunoglobulin M receptor of B-1 lymphocytes. J Exp Med 177(3):857-861.
27. Canales RD, et al. (2006) Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 24(9):1115-1122.
28. Muzio M, et al. (2008) Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: A molecular signature of anergy. Blood 112(1):188-195.
29. Herishanu Y, et al. (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117(2):563-574.
30. Morris DL, Rothstein TL (1994) Decreased surface IgM receptor-mediated activation of phospholipase C gamma 2 in B-1 lymphocytes. Int Immunol 6(7):1011-1016.
31. Wong SC, et al. (2002) Peritoneal CD5+ B-1 cells have signaling properties similar to tolerant B cells. J Biol Chem 277(34):30707-30715.
32. Stilgenbauer S, et al. (2007) Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 92(9):1242-1245.
33. Shanafelt TD, et al. (2008) Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 26(14):e5-e6.
34. Efremov DG, Gobessi S, Longo PG (2007) Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev 7(2): 102-108.
35. Chen L, et al. (2002) Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100(13):4609-4614.
36. Mockridge CI, et al. (2007) Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 109(10):4424-4431.
37. Kostareli E, et al. (2010) Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution. Leukemia 24(7):1317-1324.
38. Ghia P, Scielzo C, Frenquelli M, Muzio M, Caligaris-Cappio F (2007) From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 7(2):127-131.
39. Gurrieri C, et al. (2002) Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification. J Exp Med 196(5):629-639.
40. Tumang JR, Hastings WD, Bai C, Rothstein TL (2004) Peritoneal and splenic B-1 cells are separable by phenotypic, functional, and transcriptomic characteristics. Eur J Immunol 34(8):2158-2167.
41. Calissano C, et al. (2009) In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 114(23):4832-4842.
42. van Gent R, et al. (2008) In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. Cancer Res 68(24):10137-10144.
43. Gauld SB, Benschop RJ, Merrell KT, Cambier JC (2005) Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 6(11): 1160-1167.
44. Hayden RE, Pratt G, Roberts C, Drayson MT, Bunce CM (2012) Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leuk Lymphoma 53(4):537-549.
45. Patten PE, et al. (2012) IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. Blood 120(24):4802-4811.
46. Hoellenriegel J, et al. (2012) Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-1583.
47. Hoellenriegel J, et al. (2011) The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603-3612.
48. Ponader S, et al. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-1189.